GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Krystal Biotech Inc (NAS:KRYS) » Definitions » ROE %

Krystal Biotech (Krystal Biotech) ROE % : 4.53% (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Krystal Biotech ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Krystal Biotech's annualized net income for the quarter that ended in Dec. 2023 was $34.77 Mil. Krystal Biotech's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $767.29 Mil. Therefore, Krystal Biotech's annualized ROE % for the quarter that ended in Dec. 2023 was 4.53%.

The historical rank and industry rank for Krystal Biotech's ROE % or its related term are showing as below:

KRYS' s ROE % Range Over the Past 10 Years
Min: -397.92   Med: -14.55   Max: 1.71
Current: 1.71

During the past 8 years, Krystal Biotech's highest ROE % was 1.71%. The lowest was -397.92%. And the median was -14.55%.

KRYS's ROE % is ranked better than
83.15% of 1359 companies
in the Biotechnology industry
Industry Median: -44.11 vs KRYS: 1.71

Krystal Biotech ROE % Historical Data

The historical data trend for Krystal Biotech's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Krystal Biotech ROE % Chart

Krystal Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial -12.08 -13.00 -15.71 -25.09 1.68

Krystal Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.12 -35.82 -23.25 45.84 4.53

Competitive Comparison of Krystal Biotech's ROE %

For the Biotechnology subindustry, Krystal Biotech's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Krystal Biotech's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Krystal Biotech's ROE % distribution charts can be found below:

* The bar in red indicates where Krystal Biotech's ROE % falls into.



Krystal Biotech ROE % Calculation

Krystal Biotech's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=10.932/( (522.231+778.641)/ 2 )
=10.932/650.436
=1.68 %

Krystal Biotech's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=34.768/( (755.948+778.641)/ 2 )
=34.768/767.2945
=4.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Krystal Biotech  (NAS:KRYS) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=34.768/767.2945
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(34.768 / 168.572)*(168.572 / 804.3525)*(804.3525 / 767.2945)
=Net Margin %*Asset Turnover*Equity Multiplier
=20.63 %*0.2096*1.0483
=ROA %*Equity Multiplier
=4.32 %*1.0483
=4.53 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=34.768/767.2945
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (34.768 / 42.628) * (42.628 / 12.552) * (12.552 / 168.572) * (168.572 / 804.3525) * (804.3525 / 767.2945)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.8156 * 3.3961 * 7.45 % * 0.2096 * 1.0483
=4.53 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Krystal Biotech ROE % Related Terms

Thank you for viewing the detailed overview of Krystal Biotech's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Krystal Biotech (Krystal Biotech) Business Description

Traded in Other Exchanges
Address
2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future.
Executives
Krish S Krishnan director, 10 percent owner, officer: President and CEO 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Suma Krishnan director, 10 percent owner, officer: Chief Operating Officer 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Catherine Mazzacco director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Daniel Janney director PO BOX 7414, JACKSON WY 83002
Andrew C. Orth officer: Chief Commercial Officer 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Kathryn Romano officer: Chief Accounting Officer C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Dino A Rossi director 61 WATROO POINT, DANIEL ISLAND SC 29492
Everett Rand Sutherland director 29 HARTWELL AVENUE, LEXINGTON MA 02421
Christopher Mason director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Jing L. Marantz director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Julian S Gangolli director 4955 BASELINE AVENUE, SANTA YNEZ CA 93460
Jennifer Chien officer: Chief Commercial Officer C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Antony A Riley officer: Chief Financial Officer C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 94538
R Douglas Norby director C/O MAGNACHIP SEMICONDUCTOR, INC., 20400 STEVENS CREEK BOULEVARD, SUITE 370, CUPERTINO CA 95014
Sun Pharma (netherlands) B.v. 10 percent owner POLARISAVENUE 87, 2132 JH HOOFDDORP P7 00000